TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hagens Berman
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Alvotech experienced significant investor backlash after revealing FDA manufacturing deficiencies that impacted its 2025 revenue projections, causing a 33% stock price drop.

Insights
WFCpC   neutral

Mentioned as top holding in Monte Financial Group's portfolio with no specific performance details


ALVO   negative

Company received a Complete Response Letter (CRL) from FDA, reduced 2025 revenue guidance by 10%, adjusted EBITDA by 58%, and experienced a 33% stock price decline due to manufacturing facility issues